Clinical Report: Mechanisms Related to Gut Microbiota and Natural Polysaccharides

Overview

This systematic review summarizes preclinical evidence on the antidepressant efficacy of natural polysaccharides, focusing on their effects on gut microbiota and related metabolic pathways.

Background

Depression is a significant public health issue affecting over 300 million individuals globally, with complex pathophysiology involving multiple biological systems. Traditional antidepressant therapies often yield only moderate relief.

Data Highlights

Twenty preclinical studies met the inclusion criteria, showing that polysaccharide treatment was associated with improved depression-like behaviors, normalized neurotransmitter levels, and reduced inflammation and oxidative stress.

Key Findings

• Natural polysaccharides may improve depression-like behaviors in preclinical models.
• Polysaccharide treatment is linked to normalized neurotransmitter levels.
• There is a reduction in inflammation and oxidative stress with polysaccharide treatment.
• Changes in intestinal barrier function and gut microbiota composition were observed.
• Substantial heterogeneity and high risk of bias limit causal interpretations of the findings.

Clinical Implications

Further research is necessary to establish the efficacy and safety of natural polysaccharides in clinical settings.

Conclusion

Natural polysaccharides have been studied for their antidepressant effects in preclinical models, but further studies are needed.

Related Resources & Content

1. Frontiers in Psychiatry, 2026 -- Integrative mechanisms and intervention targets of the microbiota–gut–brain axis in depressive disorders
2. Journal of Gastroenterology, 2012 -- Impact of Serotonergic Psychoactive Medications on Gastrointestinal Function and Symptoms in Functional GI Disorders
3. Frontiers in Immunology, 2026 -- The dual-sensitive period gut-brain crosstalk, neuroinflammation, and the biological roots of adolescent depression
4. NICE guideline NG222, 2026 -- January 2026 exceptional surveillance of depression in adults: treatment and management
5. Frontiers in Immunology — The Gut Microbiota-Immune-Brain Axis in Post-Traumatic Stress Disorder: Mechanistic Integration and Translational Prospects
6. Efficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysis
7. Alterations of short-chain fatty acids in depression and effects of probiotics/prebiotics interventions on levels and clinical symptoms: a systematic review and meta-analysis
8. January 2026 exceptional surveillance of depression in adults: treatment and management (NICE guideline NG222)